ES2618353T3 - Clasificación de tumores y pronóstico del cáncer de mama - Google Patents

Clasificación de tumores y pronóstico del cáncer de mama Download PDF

Info

Publication number
ES2618353T3
ES2618353T3 ES08872935T ES08872935T ES2618353T3 ES 2618353 T3 ES2618353 T3 ES 2618353T3 ES 08872935 T ES08872935 T ES 08872935T ES 08872935 T ES08872935 T ES 08872935T ES 2618353 T3 ES2618353 T3 ES 2618353T3
Authority
ES
Spain
Prior art keywords
ratio
subject
index
classified
cut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08872935T
Other languages
English (en)
Spanish (es)
Inventor
Mark G. Erlander
Xiao-Jun Ma
Dennis Sgroi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheranostics Inc
Original Assignee
Biotheranostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheranostics Inc filed Critical Biotheranostics Inc
Application granted granted Critical
Publication of ES2618353T3 publication Critical patent/ES2618353T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES08872935T 2007-09-06 2008-09-06 Clasificación de tumores y pronóstico del cáncer de mama Active ES2618353T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97052907P 2007-09-06 2007-09-06
PCT/US2008/075528 WO2009108215A1 (en) 2007-09-06 2008-09-06 Tumor grading and cancer prognosis

Publications (1)

Publication Number Publication Date
ES2618353T3 true ES2618353T3 (es) 2017-06-21

Family

ID=40790735

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08872935T Active ES2618353T3 (es) 2007-09-06 2008-09-06 Clasificación de tumores y pronóstico del cáncer de mama

Country Status (7)

Country Link
US (3) US9447470B2 (enExample)
EP (1) EP2195467B1 (enExample)
JP (2) JP2010538609A (enExample)
CN (1) CN102395682B (enExample)
CA (1) CA2698569A1 (enExample)
ES (1) ES2618353T3 (enExample)
WO (1) WO2009108215A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
DK1899484T3 (da) * 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv
WO2010151731A1 (en) * 2009-06-26 2010-12-29 University Of Utah Research Foundation Materials and methods for the identification of drug-resistant cancers and treatment of same
CN103998064A (zh) 2010-12-09 2014-08-20 生物诊断治疗公司 治疗后的乳腺癌预后
US20120269418A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
WO2013173756A1 (en) 2012-05-18 2013-11-21 University Of North Dakota A method for quantifying proteins and isoforms thereof
CA2874492C (en) * 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
CA2923166A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
BR112016005225B1 (pt) * 2013-09-11 2023-11-14 Bio Theranostics, Inc Métodos para avaliar câncer de mama em um indivíduo
WO2015184182A1 (en) * 2014-05-29 2015-12-03 Biotheranostics, Inc Predicting likelihood of response to combination therapy
WO2017083675A1 (en) 2015-11-13 2017-05-18 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
CN107119055A (zh) * 2017-05-18 2017-09-01 南京中医药大学 分子标志物bub1b基因及其应用
CN110021433B (zh) * 2017-08-30 2023-11-17 中山大学 一种用于精准预测胃肠胰神经内分泌肿瘤患者预后的系统
JP7571006B2 (ja) * 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
CN109706160A (zh) * 2019-02-22 2019-05-03 广西医科大学 重组人蛋白激酶Nek2蛋白表达和纯化方法
KR102405973B1 (ko) 2019-09-20 2022-06-07 고려대학교 산학협력단 유방암 초음파 영상과 유전자 정보를 이용한 유방암 치료법 선택을 위한 정보를 제공하는 방법
KR102508210B1 (ko) * 2020-10-16 2023-03-10 고려대학교 산학협력단 유방암 초음파 영상을 이용한 dna 유전자 정보를 제공하는 방법
CN115029437A (zh) * 2022-04-28 2022-09-09 深圳市陆为生物技术有限公司 检测样本中生物标志物的试剂在制备乳腺癌患者化疗响应评估产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
AU1820100A (en) 1998-11-13 2000-06-05 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US20030228575A1 (en) * 2001-01-31 2003-12-11 Yuk Ming Dennis Lo Combination of circulating epstein-barr virus (EBV) DNA in the serum or plasma of patients and a method to assess EBV subtypes for the prediction and detection of epstein-barr virus associated cancers
WO2002092854A2 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
WO2002101357A2 (en) * 2001-06-10 2002-12-19 Irm Llc Molecular signatures of commonly fatal carcinomas
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
HUE050365T2 (hu) * 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20090252721A1 (en) * 2003-09-18 2009-10-08 Thomas Buschmann Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
CA2539107A1 (en) * 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
US7498693B2 (en) 2004-02-18 2009-03-03 Diversified Technologies, Inc. More compact and higher reliability power source system
CN101356532B (zh) * 2005-05-13 2012-08-01 布鲁塞尔自由大学 基于基因的算法型癌症预后
DK1899484T3 (da) * 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv

Also Published As

Publication number Publication date
US12492432B2 (en) 2025-12-09
CN102395682A (zh) 2012-03-28
JP2015057055A (ja) 2015-03-26
CN102395682B (zh) 2015-09-30
WO2009108215A1 (en) 2009-09-03
US11021754B2 (en) 2021-06-01
EP2195467B1 (en) 2016-12-14
US20180291461A1 (en) 2018-10-11
US9447470B2 (en) 2016-09-20
CA2698569A1 (en) 2009-09-03
EP2195467A1 (en) 2010-06-16
JP2010538609A (ja) 2010-12-16
US20210371934A1 (en) 2021-12-02
US20110136680A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
ES2618353T3 (es) Clasificación de tumores y pronóstico del cáncer de mama
Wreesmann et al. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma
Budczies et al. Classical pathology and mutational load of breast cancer–integration of two worlds
Zhao et al. Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA
Rodríguez-Suárez et al. Urine as a source for clinical proteome analysis: from discovery to clinical application
Kanemasa et al. Beta‐2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B‐cell lymphoma
Manatakis et al. Association of baseline neutrophil‐to‐lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma
Ebrahimi et al. The prognosis of N2b and N2c lymph node disease in oral squamous cell carcinoma is determined by the number of metastatic lymph nodes rather than laterality: evidence to support a revision of the American Joint Committee on Cancer staging system
Passoni et al. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis
MX374827B (es) Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer.
EA035451B9 (ru) Способ диагностики рака с использованием геномного секвенирования
NZ616755A (en) Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Xu et al. The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
Ball et al. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer
Granit et al. Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition
Jiang et al. Overexpression of LncRNA GHET1 predicts an unfavourable survival and clinical parameters of patients in various cancers
Shen et al. Worse characteristics can predict survival effectively in bilateral primary breast cancer: A competing risk nomogram using the SEER database
Gao et al. Impact of examined lymph node count and lymph node density on overall survival of penile cancer
CN107561280A (zh) 一种预测乳腺癌复发的试剂盒
WO2018093236A3 (ko) 유방암 환자의 예후 예측 방법
Xu et al. Risk prediction of second primary malignancies in primary early-stage ovarian cancer survivors: a SEER-based national population-based cohort study
Kreppel et al. Prognostic quality of the Union Internationale Contre le Cancer/American Joint Committee on Cancer TNM classification, for cancer of the maxillary sinus
Mao et al. Development and validation of a chromatin regulator signature for predicting prognosis hepatocellular carcinoma patient